Bioactive

Tidal Grow® AgriScience Integrates Biology and Chemistry to Fundamentally Change the Future of Agriculture

Retrieved on: 
Wednesday, May 3, 2023
CPI, Equation, Farmer, Spectra, Crop protection, Agriculture, Science and technology in Asia, Bioactive, Carbon, Chemistry, Tidal, Biology, Weather, Ecosystem, ROI, Nitrogen

BELLINGHAM, Wash., May 3, 2023 /PRNewswire/ -- As the agriculture industry faces enormous challenges including labor, nutrient runoff, weather, and regulatory, Tidal Grow® AgriScience announced today its official launch with an exciting portfolio of solutions, and a powerful pipeline to build more. By leveraging novel technologies, their offerings deliver new levels of effectiveness in plant nutrition and crop protection, providing impressive ROI for growers.

Key Points: 
  • By leveraging novel technologies, their offerings deliver new levels of effectiveness in plant nutrition and crop protection, providing impressive ROI for growers.
  • "What sets us apart is our respect for and understanding of growers in every part of the crop production ecosystem.
  • Tidal Grow® Integra Technology is positioned to scale and significantly impact the $100B+ crop protection and fertilizer markets.
  • This integration of biology and chemistry fundamentally changes the future of agriculture by making cropping inputs more effective.

Samsung Canada Redefines Holistic Health + Wellness with New and Expanded Features

Retrieved on: 
Wednesday, April 20, 2022
Samsung, ECG, Body water, Ventricular fibrillation, Sinus rhythm, Television, Tablet, Twitter, Pulse, Heart rate, Bioelectrical impedance analysis, Mobile business intelligence, GLOBE, Samsung Health, Goal, Heart rate monitor, Continuity, Ecosystem, Bioactive, Instagram, Blood pressure, Health, Mobile phone, Medical device, Galaxy

MISSISSAUGA, Ontario, April 20, 2022 (GLOBE NEWSWIRE) -- Samsung Canada is encouraging users to reach their wellness goals with advanced health monitoring tools, made available in Canada through the Samsung Health Monitor app.

Key Points: 
  • MISSISSAUGA, Ontario, April 20, 2022 (GLOBE NEWSWIRE) -- Samsung Canada is encouraging users to reach their wellness goals with advanced health monitoring tools, made available in Canada through the Samsung Health Monitor app.
  • Cutting-edge wellness features include BioActive Sensor technology and Advanced Sleep & Continuity SPO2, offering some of Samsungs most advanced health and wellness capabilities to date.
  • With this new software update, Samsung is providing access to meaningful data and insights to support Canadians in advancing their health and wellness goals, said Raj Doshi, Head of Mobile Business, Samsung Canada.
  • We are excited to introduce these new features and innovations as part of our wider commitment to redefining holistic wellness.

MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021

Retrieved on: 
Monday, August 2, 2021
Medicine, Cancer, Melanoma, Tissue engineering, Medical education, Bioactive, Skin cancer, Health

An archived version of the webcast will be available for replay for 90 days in the Investors section of the MediWound website.

Key Points: 
  • An archived version of the webcast will be available for replay for 90 days in the Investors section of the MediWound website.
  • MediWoundis a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration.
  • Our strategy leverages our enzymatic technology platform, focused on next-generation bioactive therapies for burn, wound care and tissue repair.
  • MW005, is a topical biological drug for the treatment of non-melanoma skin cancers, is a clinical-stage product candidate under development.

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2021 Financial Results on August 9, 2021

Retrieved on: 
Friday, July 2, 2021
Bioactive, Biomaterial

Management will host a conference call at 5:00 p.m. Eastern Time on August 9th to discuss the results of the quarter, and provide a corporate update with a question and answer session.

Key Points: 
  • Management will host a conference call at 5:00 p.m. Eastern Time on August 9th to discuss the results of the quarter, and provide a corporate update with a question and answer session.
  • Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 1146847.
  • A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com.
  • Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine.

Lineage Announces Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem®

Retrieved on: 
Thursday, June 17, 2021
Research, Public relations, Investor relations, Communications, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Life sciences, Biology, Biotechnology, Stem cells, Cell biology, Cell therapy, Biopharmaceutical, Bioactive, HyStem®, Amasa Therapeutics, Inc., Lineage Cell Therapeutics, Inc., HYSTEM®, AMASA THERAPEUTICS, INC., LINEAGE CELL THERAPEUTICS, INC.

Under the option agreement, Amasa will purchase certain amounts of Lineages existing supply of clinical-grade HyStem biomaterial and has the right to purchase additional amounts in connection with its up to 12-month option to acquire the exclusive license.

Key Points: 
  • Under the option agreement, Amasa will purchase certain amounts of Lineages existing supply of clinical-grade HyStem biomaterial and has the right to purchase additional amounts in connection with its up to 12-month option to acquire the exclusive license.
  • From this portfolio, we continue to find opportunities to unlock value from non-core assets through option and license agreements for assets such as HyStem, stated Brian Culley, Lineage CEO.
  • Building upon this technology, the HyStem family of hydrogels are novel biomaterials that offer unique strategies for cell therapy and bioactive molecule delivery.
  • Amasa Therapeutics is a biopharmaceutical company focused on the development of novel stem cell-based targeted biological therapeutics to treat cancer patients with unmet need.

Prosidyan® Receives CE Mark for FIBERGRAFT® BG Family of Products

Retrieved on: 
Thursday, May 20, 2021
Medical specialties, Surgery, Medicine, Biomaterials, Bioactivity, Bioactive glass, Periodontology, Putty, Bioactive, Bone grafting

b'NEW PROVIDENCE, N.J., May 20, 2021 /PRNewswire-PRWeb/ --Prosidyan, Inc. ( http://www.prosidyan.com ), developer of proprietary fiber-based bioactive glass products, receives two CE (Conformit Europenne) Marks for FIBERGRAFT BG Putty, FIBERGRAFT BG Putty GPS, and FIBERGRAFT BG Morsels.

Key Points: 
  • b'NEW PROVIDENCE, N.J., May 20, 2021 /PRNewswire-PRWeb/ --Prosidyan, Inc. ( http://www.prosidyan.com ), developer of proprietary fiber-based bioactive glass products, receives two CE (Conformit Europenne) Marks for FIBERGRAFT BG Putty, FIBERGRAFT BG Putty GPS, and FIBERGRAFT BG Morsels.
  • The Company\'s second product in the line, FIBERGRAFT BG Putty, received FDA clearance in March 2015, and comprises FIBERGRAFT BG Morsels in combination with Prosidyan\'s proprietary bioactive carrier, OSSIGLIDE.
  • Prosidyan\'s latest technology, FIBERGRAFT BG Matrix launched in August 2017, uses Prosidyan\'s proprietary Type I collagen-based bioactive carrier.
  • Prosidyan is poised to revolutionize synthetic bioactive bone graft options globally, with numerous patents and a robust pipeline of products in development.\n'

MediWound to Participate in Upcoming March Investment Conferences

Retrieved on: 
Thursday, February 25, 2021
Medicine, Life sciences, Health sciences, Biomedical engineering, Tissue engineering, Melanoma, Skin cancer, Wound, Debridement, Bioactive, Biopharmaceutical

A replay of each webcast will be available on the Companys website for approximately 30 days.

Key Points: 
  • A replay of each webcast will be available on the Companys website for approximately 30 days.
  • MediWound is a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration.
  • EscharEx, our next-generation bioactive topical therapeutic under development in the U.S. for debridement of chronic and hard to heal wounds.
  • MediWounds third innovative product candidate, MWPC005, is a topical drug under development for the treatment of non-melanoma skin cancer.

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March

Retrieved on: 
Tuesday, February 9, 2021
Bioactive, Biomaterial

Management will participate in a virtual fireside chat on Wednesday, February 24 at 8:40 a.m. Eastern Time.

Key Points: 
  • Management will participate in a virtual fireside chat on Wednesday, February 24 at 8:40 a.m. Eastern Time.
  • Live audio webcasts of the conference presentations will be accessible by visiting the Upcoming Events section on the Investor Relations page of Organogenesiss website www.organogenesis.com.
  • Archives of the webcasts will be available for replay following the conference for approximately 30 days.
  • Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine.

Biomaterials Market worth $47.5 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, January 18, 2021
Biomaterials, Biomolecules, Ceramic, Bioactive

The metallic biomaterials segment accounted for the largest share of the type segment in the market in 2019.

Key Points: 
  • The metallic biomaterials segment accounted for the largest share of the type segment in the market in 2019.
  • On the basis type of materials, the biomaterials market is broadly segmented into Metallic, Polymeric, Ceramic, and Natural biomaterials.
  • In 2019, Metallic biomaterials accounted for the largest share of the market.
  • Medical Ceramics Market by Material (Zirconia, Alumina, Hydroxyapatite, Glass, Bioresorbable, Bioinert, Bioactive, Piezoceramics), Application (Dental, Orthopedic, Cardiovascular, Diagnostic, Surgical Implants, Dermal Fillers) - Global Forecast to 2025

Biomaterials Market worth $47.5 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, January 18, 2021
Biomaterials, Biomolecules, Ceramic, Bioactive

The metallic biomaterials segment accounted for the largest share of the type segment in the market in 2019.

Key Points: 
  • The metallic biomaterials segment accounted for the largest share of the type segment in the market in 2019.
  • On the basis type of materials, the biomaterials market is broadly segmented into Metallic, Polymeric, Ceramic, and Natural biomaterials.
  • In 2019, Metallic biomaterials accounted for the largest share of the market.
  • Medical Ceramics Market by Material (Zirconia, Alumina, Hydroxyapatite, Glass, Bioresorbable, Bioinert, Bioactive, Piezoceramics), Application (Dental, Orthopedic, Cardiovascular, Diagnostic, Surgical Implants, Dermal Fillers) - Global Forecast to 2025